Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Key growth drivers and launches continue momentum in Q3 1 GROWTH Q3 sales1 Entresto sacubitril/valsartan Sales USD Million 924 Growth vs. PY USD Million Key growth drivers and launches Growth vs. PY 53% of IM sales, growing 26% in Q3 CC AimovigⓇ 292 44% Cosentyx 1,247 235 22% (secukinumab) Kesimpta 53% +26% vs. PY MayzentⓇ PiqrayⓇ 109 (ofatumumab) JAKAVI 426 ruxolitinib 97 91 108 nm XiidraⓇ 45% 26% KesimptaⓇ LutatheraⓇ zolgensma 375 84 28% 36% KymriahⓇ PROMACTA® 522 (eltrombopag) 80 18% KisqaliⓇ 28% ILARIS 272 52 24% (canakinumab). KISQALI 232 49 27% ribociclib Xolair 365 45 13% Omalizumab MAYZENT. llarisⓇ ZolgensmaⓇ Tafinlar+MekinistⓇ JakaviⓇ PromactaⓇ 76 27 55% (siponimod) tablets KYMRIAH 146 24 20% (tisagenlecleucel) Tafinlar. + Mekinist. 417 20 4% nm - not meaningful Q3 2018 Q3 2019 Q3 2020 *Includes Xolair®, BeovuⓇ, Adakveo®, TabrectaⓇ, Luxturna®, Enerzair, AtecturaⓇ and Leqvio® 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY EntrestoⓇ Cosentyx® Q3 2021 Other 7 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation